SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is trending as escalating Middle East tensions, particularly concerning the Strait of Hormuz, fuel community speculation about a significant surge in oil prices and a potential short squeeze, with many comparing its current trajectory to previous parabolic runs during geopolitical conflicts.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as escalating geopolitical tensions and news of a standoff between the Pentagon and AI provider Anthropic are driving conversation around its critical role in defense AI. The community is actively discussing how this reinforces Palantir's position as a trusted, model-agnostic platform, leading to strong bullish sentiment and calls for significant upward movement.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the escalating Middle East conflict, marked by US strikes and threats to critical oil shipping lanes, drives a sharp community debate. Investors are split between anticipating a market downturn due to geopolitical risks and rising oil prices, versus those expecting a 'buy the dip' recovery on the belief that tensions are already priced in or that peace talks will prevail.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending as recent geopolitical uncertainty boosts interest in defense technology, while community discussions also focus on the company's participation in the "Drone Dominance" program and upcoming "Innovation Day," creating both high expectations for future contracts and ongoing debate about management's execution.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is trending as escalating geopolitical tensions in the Middle East, specifically concerning Iran and the Strait of Hormuz, are driving a significant surge in oil prices. The community is highly engaged, anticipating substantial gains for the energy sector amidst potential supply disruptions, while others express caution regarding the sustainability of the rally.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is trending due to better-than-expected earnings and highly optimistic guidance for its next-generation 800G and 1.6T products, driven by surging demand from AI data centers. The community is sharply divided, with bulls highlighting aggressive revenue projections and analyst upgrades, while bears raise concerns about the company's profitability, valuation, and a recently announced at-the-market stock offering.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is buzzing as its highly engaged community actively expands a diverse real-world brand, featuring Kendu Spice, energy drinks, and ongoing events, while members enthusiastically buy dips, reinforcing their conviction in its long-term potential.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is surging amid escalating geopolitical tensions in the Middle East and strong financial performance, including a recent agreement to quadruple THAAD missile production and an upbeat outlook. The community is keenly discussing the 'war effect' driving a 'defense super-cycle,' even as some express caution about the stock's rapid run.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp. is experiencing a surge as escalating geopolitical tensions in the Middle East fuel speculation of an oil supply shock, with the community actively discussing its low float and high short interest for a potential short squeeze if the conflict intensifies.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund (XLE) is under intense focus as escalating geopolitical tensions, including US-Israel strikes on Iran and severe disruption to tanker traffic in the Strait of Hormuz, ignite expectations for a substantial oil price surge. The community is actively debating the potential for crude to reach $100 or even higher, driving a significant rotation into the energy sector amidst concerns of a prolonged supply shock from the critical chokepoint.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioXcel Files SNDA To Expand IGALMI Label For At-Home Setting

(RTTNews) - BioXcel Therapeutics, Inc. (BTAI) said on Tuesday that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for IGALMI, seeking approval...

Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) breached their fiduciary duties to shareholders. If...

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -41.56% and -34.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

BioXcel Therapeutics, Inc. (BTAI) announced on Wednesday that its BXCL501 demonstrated continued effects and consistent benefit with repeat dosing in the treatment of agitation associated with bipolar disorders or schizophrenia in a late-stage trial.BXCL501 is an investigational, orally dissolving film formulation of Dexmedetomidine, marketed by the company as Igalmi. While the primary objective of the trial was to ascertain the safety of the formulation in an at-home setting, the continued effects and consistent benefits observed with repeat dosing in the trial further support the potential of BXCL501 for use in the outpatient setting, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-reports-positive-topline-exploratory">said</a>.Shares of the company rose 3% in the pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BTAI">BTAI stock</a> rose from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.BioXcel <a href="https://stocktwits.com/news-articles/markets/equity/bioxcel-sublingual-film-well-tolerated-in-bipolar-schizophrenia-trial-in-at-home-settings/chsU5sURdl5">reported</a> late last month that the drug was well-tolerated in the study. The company said that the data from the study will form the basis of a submission to the U.S. Food and Drug Administration (FDA) slated for the first quarter of 2026 and aimed at expanding the label for Dexmedetomidine in the at-home setting.“These positive results, along with the safety and tolerability data previously announced, reinforce BXCL501’s potential in the at-home setting where there is substantial unmet need with no FDA-approved options currently available,” said BioXcel CEO Vimal Mehta.The company said that a total of 246 patients were part of the trial, and 2,437 agitation episodes in 208 patients were treated. All patients were able to successfully self-administer the film, and an average of 11.7 agitation episodes were recorded per treated patient.Igalmi is already approved for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in medically supervised settings.BTAI stock is down by 40% this year and by 59% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-lower-ahead-of-inflation-data/chwkJpfRduc">Dow Futures Edge Lower As Investors Turn Cautious Ahead Of Inflation Data: ORCL, KLAR, HOOD, GME Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study

The company stated that the continued effects and consistent benefits observed with repeat dosing in the trial support the potential of BXCL501 for use in the outpatient setting. 

Equity

BioXcel Therapeutics, Inc. (BTAI) on Wednesday said that its late-stage trial evaluating the safety of the company’s BXCL501 as a treatment for agitation associated with bipolar disorders or schizophrenia in the at-home setting met its primary goal of being well-tolerated.BXCL501 is an investigational, orally dissolving film formulation of Dexmedetomidine. The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-announces-serenity-home-pivotal-phase-3">said</a> that the data from the study will form the basis of a submission to the U.S. Food and Drug Administration slated for the first quarter of 2026 and aimed at expanding the label for its dexmedetomidine sublingual film called Igalmi in the at-home setting.Igalmi is already approved for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in medically supervised settings.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BTAI">BTAI stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:624/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_27_at_9_42_20_AM_png_54402b6e8c.webp" alt="BTAI's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Aug. 27, 2025 | Source: Stocktwits" width="624" height="65"><figcaption>BTAI's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Aug. 27, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user recommended buying the shares of the company.<stembedurl>https://stocktwits.com/Michael17711771/message/626688937</stembedurl>Another user opined that the study results are very promising long term.<stembedurl>https://stocktwits.com/They_call_me_tater_salad/message/626688733</stembedurl>BioXcel said that no discontinuations due to tolerability were observed in the arm of the study that received BXCL501.“By meeting its primary endpoint, the SERENITY At-Home Pivotal Phase 3 trial reinforces BXCL501’s potential to be safely used at home like it is already used in the previously FDA approved institutional setting. The unmet medical need in the at-home setting is significant with no FDA-approved treatments,” CEO Vimal Mehta said, while adding that the company believes the total addressable market is “significantly larger” than previously reported.The company said that a total of 246 patients were part of the trial, and 2,437 agitation episodes in 208 patients were treated. All patients were able to successfully self-administer the film, and an average of 11.7 agitation episodes were recorded per treated patient.The company said that available data demonstrate that treatment with BXCL501 regularly reduced symptoms of agitation throughout the trial. A greater percentage of patients experiencing mild, moderate, or severe agitation had full resolution of symptoms in the BXCL501 arm compared with placebo. Complete analyses of the full data set are ongoing and will be shared in time, the company said.BTAI stock is down by 24% this year and by 57% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/mannkind-united-therapeutics-expand-agreement-to-develop-second-investigational-molecule-together/chsURMTRdkC">MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

BioXcel’s Sublingual Film Well-Tolerated In Bipolar, Schizophrenia Trial In At-Home Settings, Retail Says Buy Now Or Regret Later

The company said that no discontinuations due to tolerability were observed in the arm of the study that received BXCL501.

BioXcel Therapeutics drew sharp retail-trader attention early Wednesday as the company gears up to release topline results later in the day for its experimental therapy to treat agitation linked to bipolar disorders and schizophrenia outside of clinical settings.The report from its SERENITY At-Home Phase 3 safety trial will reveal detailed effects of BXCL501, marketed as Igalmi, the company's sublingual film formulation of dexmedetomidine. The company plans to hold an investor call and webcast at 8 a.m. ET to discuss the data.The announcement about the release, made late Tuesday, triggered a 19% spike in&nbsp;<a href="https://stocktwits.com/symbol/BTAI">BioXcel's stock</a> after the bell, sending the ticker to the top of trending symbols on Stocktwits, accompanied by a 118% surge in 24-hour message volume. Sentiment, however, was ‘neutral’ as of the last reading.<figure class="image"><img style="aspect-ratio:1310/194;" src="https://news.stocktwits-cdn.com/BTAI_stock_sentiment_and_message_volume_on_Aug_27_png_6d08b1cb22.webp" alt="BTAI stock sentiment and message volume on Aug 27.png" width="1310" height="194"><figcaption>BTAI stock sentiment and message volume on Aug 27 as of 3:30 am ET | source: Stocktwits</figcaption></figure>Last week, BioXcel captured investors' attention after the company<a href="https://stocktwits.com/news-articles/markets/equity/bio-xcel-stock-in-focus-fda-issues-positive-early-feedback-ahead-of-key-meeting-on-expanded-psychiatric-label-1/chsOR5KRdQ1">&nbsp;said</a> the FDA had provided positive preliminary comments for Igalmi.The trial enrolled 200 patients living with bipolar disorder or schizophrenia who experienced agitation episodes despite being on stable treatment. Over 12 weeks, participants self-administered either 120 mcg of BXCL501, the same dose approved under medical supervision, or a placebo when symptoms arose.The trial tracked adverse events as its primary safety endpoint, while patients or caregivers also provided feedback using a modified global impression of severity scale.Igalmi is also being studied for agitation associated with Alzheimer's dementia, bipolar disorder, and schizophrenia in outpatient and at-home settings. It has received an FDA breakthrough therapy designation for agitation linked to dementia and a fast-track designation for agitation tied to schizophrenia, bipolar disorders, and dementia.BioXcel's stock short interest has also plunged since March, from over 10.6% to 1.8% as of the end of last week, according to Koyfin data.Shares of the company have shed nearly 15% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/firefly-neuroscience-stock-scores-biggest-gain-in-weeks-on-nvidia-brain-platform-boost/chsxnkFRdkQ">Firefly Neuroscience Stock Scores Biggest Gain In Weeks On Nvidia Brain Platform Boost</a>

BioXcel's trial enrolled 200 patients living with bipolar disorder or schizophrenia who experienced agitation episodes despite being on stable treatment. | Representative image via Getty Images

BioXcel Sparks Retail Frenzy As Stock Soars Ahead Of Phase 3 Results For Bipolar, Schizophrenia Drug

Shares surged after hours on Tuesday, making BioXcel the most talked-about stock on Stocktwits, with message volume up 118% in the 24 hours following the announcement.

All Eyes On BioXcel Stock As Phase 3 Data For Bipolar, Schizophrenia Drug Due Today

Shares surged after hours on Tuesday, making BioXcel the most talked-about stock on Stocktwits, with message volume up 118% in the 24 hours following the announcement.


Retail chatter surged around BioXcel Therapeutics early Monday after the company said it received positive preliminary FDA comments ahead of an&nbsp;Aug. 20&nbsp;meeting to discuss expanding Igalmi’s label for at-home use in agitation tied to bipolar disorder and schizophrenia.The FDA’s remarks focused on aligning with the company over the format and content of the upcoming&nbsp;supplemental new drug application (sNDA)&nbsp;submission. BioXcel said it is evaluating the comments and expects to provide an update following the meeting.&nbsp;Currently, Igalmi is approved for hospital or supervised clinical use, and a green light for outpatient administration would open a new, significantly larger commercial opportunity.The regulatory update comes on the heels of BioXcel completing its Serenity At-Home Phase 3 trial earlier this month, with&nbsp;the&nbsp;last patient visits finalized across 22 U.S. sites.&nbsp;The pivotal study enrolled more than 200 patients and is designed to assess the safety of a 120 mcg self-administered dose of BXCL501 for acute agitation episodes in home settings. Top-line data are expected later this quarter and will form the backbone of the planned sNDA filing.The FDA has previously granted BXCL501 Breakthrough Therapy designation for dementia-related agitation and Fast Track status for schizophrenia, bipolar disorder, and dementia.&nbsp;BioXcel has also received two favorable recommendations from its Data Safety Monitoring Board, supporting the drug’s advancement toward regulatory review.Last Friday, H.C. Wainwright boosted its price target on the stock to $10 from $8 while sticking with a Buy rating, pointing to growing excitement around BXCL501.&nbsp;The brokerage firm called the upcoming Serenity trial readout “low-risk” and expects the company&nbsp;to&nbsp;file for an expanded label by the end of the year, with the FDA potentially signing off in the second half of 2026.On Aug. 6, BioXcel said a new paper in Frontiers in Pharmacology highlighted dexmedetomidine, the key ingredient in BXCL501.The study showed it could significantly influence stress-related behaviors in preclinical models, raising the possibility that the drug’s use might extend beyond calming acute agitation to helping manage longer-term psychiatric conditions.On Stocktwits, retail sentiment for BioXcel was described as ‘extremely bullish’ with ‘extremely high’ message volume, making it the platform’s most trending stock.One user urged that “$BTAI could be pushed over $50 this week” if investors “stick together,” adding that the community had the power to make it happen.&nbsp;<stembedurl>https://stocktwits.com/Eastcoasttrader11/message/625574895</stembedurl>Another user noted that if the Aug. 20 meeting went positively, it would signal that Phase 3 data had already come back strong as expected.<stembedurl>https://stocktwits.com/PejalPapa/message/625574210</stembedurl><a href="https://stocktwits.com/symbol/BTAI">BioXcel’s stock</a> has declined 8.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail chatter surged around BioXcel Therapeutics (BTAI) early Monday after the company said it received positive preliminary FDA comments. (Photo credit: Getty Images)

BioXcel Stock In Focus: FDA Issues Positive Early Feedback Ahead Of Key Meeting On Expanded Psychiatric Label 

The update comes as the company wraps up its pivotal Serenity At-Home Phase 3 trial and analysts grow more optimistic on BXCL501’s commercial potential. 

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -6.52% and -52.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks

Capricor slumps 33% as the FDA rejects its BLA for DMD drug, deramiocel, citing lack of effectiveness data and CMC issues.

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

BioXcel Therapeutics Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

Current Price	$1.67
Prev Close	$1.76
Open	$1.76
Dividend Yield	0.00%
50-Day Moving Average	$1.72
Beta	1.47
Avg. Volume	643,227.95
PE Ratio	-0.17

52-Week High	$8.08
52-Week Low	$1.17
Market Capitalization	$36.52M
EPS (Annual)	-$23.51
Price to Book	-0.38
Revenue Per Employee	$61,243.24

BTAI
BioXcel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BTAI News

BTAIBioXcel Therapeutics Inc